ZOLL Medical Receives 2010 North American Market Leadership Award

ZOLL Medical Receives 2010 North American Market Leadership Award

News Feb 02, 2011

January 27, 2011 -- CHELMSFORD, MASS -- ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of medical devices and related software solutions, announced today that it has received the Frost & Sullivan 2010 Market Leadership Award for the North American external defibrillator market. ZOLL was recognized by Frost & Sullivan as the company that has demonstrated excellence in capturing the highest market share within its industry. ZOLL has developed and markets solutions that have revolutionized critical care and advanced the practice of resuscitation through defibrillation and monitoring, circulation and CPR feedback, data management, and fluid resuscitation.

"ZOLL's products continue to embody innovation and bring new capabilities that improve the diagnosis, treatment and management of cardiac care. The result is better clinical outcomes and quality of life for patients," said Gary Burk, Frost & Sullivan Analyst. "ZOLL's ongoing commitment to improving resuscitation technology helps drive new standards. Its integrated product portfolio delivers industry-leading solutions that assist first responders, healthcare professionals, government and military entities, and lay rescuers in patient care

"This Frost & Sullivan Award recognizes our ongoing commitment to researching and developing improved ways to advance cardiac care with resuscitation technologies," said Jonathan A. Rennert, President of ZOLL. "We've made significant strides with such industry breakthroughs as Real CPR Help® and See-Thru CPR®, and now see significant potential with our broadened reach into data management and temperature management for future growth for improving patient care

For the Market Leadership Award, the following criteria were used to benchmark ZOLL Medical's performance against key competitors:

  • Breakthrough approach/degree of differentiation/innovation compared to other market participants
  • Product innovation in terms of unique or revolutionary technology
  • Penetration rate of new markets
  • Significance of innovation in the industry
  • Leading proactive initiatives to improve value to customers
  • Advancement of the industry through research
  • Implementation of a new or unique pricing strategy
  • Implementation of a new or unique marketing strategy
  • Creating new venues, such as online services, for an established product

Highlights of ZOLL's Portfolio for Strengthening Resuscitation

All of ZOLL's defibrillators, including AEDs, feature Real CPR Help, real-time CPR feedback to guide rescuers to the proper depth and rate of chest compressions. The R Series®, E Series®, and AED Pro® also offer See-Thru CPR, proprietary filtering technology that allows professional rescuers to view a patient's underlying cardiac rhythm by filtering CPR artifact during resuscitation efforts. Unique to ZOLL is the world's only wearable defibrillator, the LifeVest®, which has a 98% first shock success rate and saves a life every other day in the United States. The newest addition to ZOLL's external defibrillators is the Propaq® MD, an ultra-lightweight monitor/defibrillator with highly sophisticated, advanced capabilities for military and air medical operations.

Apart from external defibrillators, other highlights of ZOLL's portfolio include the AutoPulse®, a revolutionary non-invasive cardiac support pump with an easy-to-use, load-distributing LifeBand® that squeezes the entire chest and moves more blood more consistently than possible with manual chest compressions, and Intravascular Temperature Management Systems for critical care, which provide precise and rapid control of a patient's core temperature for both cooling and warming applications.

ZOLL's integrated critical care portfolio includes: :

  • AED Plus® Automated External Defibrillator
  • AED ProAutomated External Defibrillator
  • E Series Defibrillators
  • R Series Defibrillators
  • LifeVest® Wearable Defibrillator
  • AutoPulse Non-Invasive Cardiac Support Pump
  • CodeNet® Resuscitation Data Management System
  • Propaq® MD Monitor/Defibrillator
  • Defibrillator Electrodes
  • PocketCPR® Personal CPR Coaching Device
  • Intravascular Temperature Management (IVTMTM)
  • SurePowerTM Defibrillator Battery System
Continue Reading

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The Company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages almost 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit www.frost.com.

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and software clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company in 2007, 2008, and 2009, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.

A Pafford EMS medical helicopter crashed on Sunday night, killing all three crew members on board.
Effingham County Dive Rescue Team consists of difficult but rewarding work, like rescue missions and solving crimes with police.
The 6,700-square foot center features a dispatch center, a large main room for disaster response meetings, and a media room for relaying information during emergencies.
Owensboro Fire Department employees who recently received ALS training from Air Evac Lifeteam have had 83% resuscitation success rates in comparison to the national average of 11%.
While provider safety remains a high priority in EMS education, the topic of patient safety has fallen to the wayside.
Dispatch operators in Flagler, Florida often quit within their first twelve months of work due to the high stress of the job and average starting salary of $22,000.
Government representatives are considering new legislation and higher taxes to help support agencies that are losing volunteers.
Several cities and counties are planning to sue for the excessive costs of handling the opioid epidemic, especially for medical services, fire departments, and law enforcement.
Mothers can anonymously drop off their infants in the baby box at fire departments, which sets off a silent alarm alerting EMS personnel that it's in use.
Acushnet ambulances will be using Tylenol, Toradol, and ibuprofen as safer alternatives to fentanyl as the opioid epidemic continues to worsen.
Medline is one of the first to achieve a fentanyl-resistant product in response to the growing opioid epidemic.
A portion of ticket sales will help fund the monument in Keansburg, which will feature a piece of a steel beam from the World Trade Center.
The AAA honored SCCAD's efforts in combating the opioid epidemic with a 2017 AMBY Award in the category of Community Impact Program.
The funds will benefit organizations along the Hudson River such as Rockland Paramedic Services, Nyack Hospital, and Maternal Infant Services Network.
As one of the top ten most active emergency departments in the nation, Reading Hospital staff felt it was time to prepare for an active shooter event.